Condition

Effects of Chemotherapy

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions15

Lead sponsors shown6

Clinical trials

6 shown

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast CancerNCT03006614 · 2016-04-01

Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic LevelNCT02555592 · 2015-10-01

Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health InterventionNCT02375776 · 2015-03-01

Intestinal Microflora in Lung Cancer After ChemotherapyNCT02771470 · 2014-09-01

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer PatientsNCT01749072 · 2012-12-01

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and TrastuzumabNCT01432223 · 2011-09-01

Common interventions

CAPDRUG1 CORA- Device:smartphones"OTHER1 CTXDRUG1 DDPDRUG1 EPIDRUG1 Gefitinib groupDRUG1 GEMDRUG1 HDRUG1 Nab-paclitaxelDRUG1 NVBDRUG1 placeboDRUG1 Primary surgical resection with sequential adjuvant therapyPROCEDURE1 ProbioticsDRUG1 TDRUG1 Vinorelbine, Ifosfamide, MesnaDRUG1

Leading sponsors

Massachusetts General Hospital1 Osaka Medical College1 Peking Union Medical College Hospital1 Pusan National University Hospital1 Shandong University1 Shi Yanxia1

Trial status mix

COMPLETED3

UNKNOWN3

Phase mix

PHASE22

NA1

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.